AQST vs JAZZ
AQST: Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film platforms. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | AQST | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.94 | $250.41 | |
| Market cap as of 2026-07-23 | $496M | $16.0B | |
| P/E as of 2026-07-23 | n/a | 543.13 | |
| PEG as of 2026-07-23 | -2.03 | 58.02 | AQST lower |
| Net margin as of 2026-07-23 | -137.1% | +0.7% | JAZZ higher |
| Gross margin as of 2026-07-23 | +63.5% | +88.0% | JAZZ higher |
| Operating margin as of 2026-07-23 | -111.2% | -0.8% | JAZZ higher |
| ROE as of 2026-07-23 | -21.8% | +0.7% | JAZZ higher |
| ROA as of 2026-07-23 | -49.3% | +0.3% | JAZZ higher |
| Debt / equity as of 2026-07-23 | 4.68 | 1.18 | JAZZ lower |
| Revenue growth (YoY) as of 2026-07-23 | -7.3% | +9.2% | JAZZ higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | +5.3% | JAZZ higher |
| Beta as of 2026-07-23 | 1.45 | 0.37 | |
| 1-year return as of 2026-07-22 close | -4.5% | +125.7% | JAZZ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.